This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on Web of Science (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Statistics and Research Methods  • Drug Therapy, Other  • Hypertension  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2006;296:2787-2788.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Some researchers are questioning a claim made by the authors of a recent study that it is feasible to use drug treatment to reduce the risk that patients with prehypertension will progress to hypertension.

In that study, the Trial of Preventing Hypertension (TROPHY), participants were randomly assigned to receive an angiotensin II receptor blocker, candesartan (AstraZeneca LP, London, England), or placebo for 2 years. All patients were then given placebo and followed up for an additional 2 years (Julius S et al. N Engl J Med. 2006;354:1685-1697).

Researchers are debating the benefit of drug treatment for patients with prehypertension as there is no evidence it reduces cardiovascular morbidity and mortality.

At the 2-year mark, there was a major reduction in the number of participants progressing to hypertension in the candesartan group compared with those in the placebo group. At 4 years, the proportion of participants moving into hypertension . . . [Full Text of this Article]

END POINTS QUESTIONED



CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?